CNS Pharmaceuticals ^{Priced, Nasdaq: CNSP}

We are a preclinical stage pharmaceutical company with a focus on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors, based on intellectual property that we license under an Amended and Restated Patent License Agreement with Houston Pharmaceuticals and own pursuant to a collaboration and asset purchase agreement with Reata Pharmaceuticals. Dr. Waldemar Priebe, our founder and largest shareholder, controls HPI. We believe that our lead candidate, Berubicin, if approved by the US FDA, may be a significant improvement in the treatment of glioblastoma, a type of brain cancer which is currently considered incurable. Berubicin is an anthracycline, which is a class of drugs that are among the most powerful chemotherapy drugs known and are designed to damage the DNA of targeted cancer cells by interfering with the action of a critical enzyme enabling cell proliferation. Based on limited clinical data, we believe Berubicin is the first anthracycline that appears to have crossed the blood brain barrier; if our clinical trials are successful and if approved by the appropriate regulatory agencies, including without limitation the FDA, Berubicin would offer oncologists the only anthracycline effective against brain cancer.